Darunavir-based single pill FDC approved in EU (Symtuza)

Simon Collins, HIV i-Base

On 27 September 2017, the first protease inhibitor-based fixed dose combination (FDC) was approved in Europe by the European Medicines Agency (EMA). [1]

The once-daily FDC combines darunavir 800 mg, cobicistat 150 mg and emtricitabine/tenofovir alafenamide 200 mg/10 mg fixed-dose combination (D/C/F/TAF).

The indication is for HIV positive adults and adolescents aged 12 years and older.

The combination needs to be taken once-daily with food. Approval is based on phase 3 studies showing bioequivalence to the individual components being taken separately.

This FDC is marketed by Janssen-Cilag with the brand name Symtuza.

For full details see the SPC and patient information on the EMA website. [2]


  1. Janssen press statement. European Commission approves Symtuza for the treatment of HIV-1 in adults and adolescents in Europe. (27 September 2017).
  2. European Summary of Product Charateristics (SPC) for Symtuza. (September 2017).

Links to other websites are current at date of posting but not maintained.